Skip to main content

Table 2 Summary of Fasting Plasma Lactic Acid Concentration

From: Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

Lactic acid (mmol/L) Placebo + Metformin
(N = 17)
RE 500 mg + Metformin
(N = 16)a
RE 750 mg + Metformin
(N = 17)b
A. Summary of Maximum On-Therapy Absolute concentrations and Changefrom Baseline; Mean (SD)
Absolute Values 1.554 (0.5094) 1.220 (0.2684) 1.508 (0.4389)
Change From Baseline 0.460 (0.2289) 0.234 (0.3717) 0.249 (0.5934)
B. Summary of Repeated measures analysis ofcovariance of change from baseline (vs. placebo) on selected days
Study Day 2    
Mean (SD) 0.16 (0.266) −0.07 (0.248) −0.17 (0.419)
Difference (95% CI)   − 0.284 (− 0.485, − 0.083) −0.246(− 0.445, − 0.047)
p-value   0.0066 0.0164
Study Day 6    
Mean (SD) 0.08 (0.288) −0.26 (0.310) −0.26 (0.538)
Difference (95% CI)   −0.380 (− 0.603, − 0.157) −0.254(− 0.472, − 0.036)
p-value   0.0013 0.0232
Study Day 13    
Mean (SD) 0.00 (0.304) −0.15 (0.485) −0.33 (0.398)
Difference (95% CI)   −0.191 (− 0.414, 0.031) −0.255 (− 0.475, − 0.034)
p-value   0.0905 0.0244
  1. CI Confidence interval, RE Remogliflozin Etabonate, SD Standard deviation; a: n = 15 for Day 6 & 13; b: n = 16 for Day 13
  2. The treatment vs placebo difference is based on ANCOVA: Change = Baseline + Treatment + Visit + Treatment-by-Visit